Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

NCT02443688
completedphase_2

CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT02385760
completedphase_1

Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients

NCT01944735
completedphase_1

Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam

NCT02233244
completedphase_1

Phase 1 Study Assessing the Safety and Tolerability of CTX-4430

NCT01748838

Clinical Trials (5)

Showing 5 of 5 trials
NCT02443688Phase 2

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Completed
NCT02385760Phase 2

CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris

Completed
NCT01944735Phase 1

Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients

Completed
NCT02233244Phase 1

Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam

Completed
NCT01748838Phase 1

Phase 1 Study Assessing the Safety and Tolerability of CTX-4430

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5